These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1799 related articles for article (PubMed ID: 30506237)
21. Olanzapine: an updated review of its use in the management of schizophrenia. Bhana N; Foster RH; Olney R; Plosker GL Drugs; 2001; 61(1):111-61. PubMed ID: 11217867 [TBL] [Abstract][Full Text] [Related]
22. The promise of new drugs for schizophrenia treatment. Tamminga CA Can J Psychiatry; 1997 Apr; 42(3):265-73. PubMed ID: 9114942 [TBL] [Abstract][Full Text] [Related]
23. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Kane JM; Leucht S; Carpenter D; Docherty JP; J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142 [TBL] [Abstract][Full Text] [Related]
24. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935 [TBL] [Abstract][Full Text] [Related]
25. Practical issues with amisulpride in the management of patients with schizophrenia. Pani L; Villagrán JM; Kontaxakis VP; Alptekin K Clin Drug Investig; 2008; 28(8):465-77. PubMed ID: 18598092 [TBL] [Abstract][Full Text] [Related]
26. New generation antipsychotics for first episode schizophrenia. Rummel C; Hamann J; Kissling W; Leucht S Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012 [TBL] [Abstract][Full Text] [Related]
27. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Leucht S; Pitschel-Walz G; Engel RR; Kissling W Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257 [TBL] [Abstract][Full Text] [Related]
28. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. Li X; Guo X; Fan X; Feng T; Wang C; Yao Z; Xu X; Chen Z; Wang H; Xie S; He J; Zhuo K; Xiang Q; Cen H; Wang J; Smith RC; Jin H; Keshavan MS; Marder SR; Davis JM; Jiang K; Xu Y; Liu D Schizophr Res; 2021 Apr; 230():87-94. PubMed ID: 33279374 [TBL] [Abstract][Full Text] [Related]
29. Amisulpride - is it as all other medicines or is it different? An update. Hadryś T; Rymaszewska J Psychiatr Pol; 2020 Oct; 54(5):977-989. PubMed ID: 33529280 [TBL] [Abstract][Full Text] [Related]
30. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Krause M; Zhu Y; Huhn M; Schneider-Thoma J; Bighelli I; Chaimani A; Leucht S Eur Neuropsychopharmacol; 2018 Jun; 28(6):659-674. PubMed ID: 29802039 [TBL] [Abstract][Full Text] [Related]
31. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402 [TBL] [Abstract][Full Text] [Related]
32. Novel antipsychotics: comparison of weight gain liabilities. Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912 [TBL] [Abstract][Full Text] [Related]
33. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. Harvey RC; James AC; Shields GE CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655 [TBL] [Abstract][Full Text] [Related]
34. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354 [TBL] [Abstract][Full Text] [Related]
35. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566 [TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis. Leucht S; Schneider-Thoma J; Burschinski A; Peter N; Wang D; Dong S; Huhn M; Nikolakopoulou A; Salanti G; Davis JM World Psychiatry; 2023 Jun; 22(2):315-324. PubMed ID: 37159349 [TBL] [Abstract][Full Text] [Related]
37. Risperidone versus other atypical antipsychotic medication for schizophrenia. Gilbody SM; Bagnall AM; Duggan L; Tuunainen A Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551 [TBL] [Abstract][Full Text] [Related]
39. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cipriani A; Boso M; Barbui C Cochrane Database Syst Rev; 2009 Jul; (3):CD006324. PubMed ID: 19588385 [TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. Men P; Yi Z; Li C; Qu S; Xiong T; Yu X; Zhai S BMC Psychiatry; 2018 Sep; 18(1):286. PubMed ID: 30185173 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]